

Midtown Building, Suite 400 1301 Atlantic Avenue Atlantic City, NJ 08401-7212 Tel 609.348.4515 Fax 609.348.6834 www.foxrothschild.com

Eileen Oakes Muskett, Esquire Direct Dial: (609) 572-2355

Email Address: emuskett@foxrothschild.com



June 7, 2018

VIA OVERNIGHT DELIVERY

Honorable Glenn A. Grant Acting Administrative Director of the Courts Attention: MCL Comments - Zostavax Vaccine Hughes Justice Complex, P.O. Box 037 Trenton, New Jersey 08625-0037

> Re: Response of Merck & Co., Inc. and Merck Sharp & Dohme Corp.

> > to Applications for Multicounty Litigation Designation of ZOSTAVAX®

Litigation

Dear Judge Grant:

On behalf of Merck & Co., Inc. and Merck Sharp & Dohme Corp. (collectively, "Merck"), I write in response to the Court's May 9, 2018 Notice to the Bar concerning two pending applications for Multicounty Litigation ("MCL") designation of New Jersey state-court litigation involving personal injuries attributed to Zostavax, Merck's FDA-approved vaccine to help protect against herpes zoster (shingles).

Under the particular circumstances of this litigation, Merck does not oppose the establishment of an MCL for lawsuits alleging personal injury damages purportedly resulting from Zostavax. Merck also does not oppose the request of Marc J. Bern & Partners LLP that the Court assign any MCL established for this litigation to the Honorable Judge James F. Hyland of the Superior Court of New Jersey for Middlesex County.

> Very truly yours, Seileen Oakes Muskett

Eileen Oakes Muskett

Cc:

Marc J. Bern & Partners LLP Law Offices of Sadaka Associates